Secukinumab treated patients in the Australian clinical practice setting: HOPE study investigating the quality of life in patients with severe chronic plaque psoriasis after treatment

被引：0
|
作者：
Foley, P. [1 ]
Walsh, M. [2 ]
Mate, E. [2 ]
机构：
[1] Skin & Canc Fdn Inc, Carlton, Vic, Australia
[2] Novartis Pharmaceut Australia Pty Ltd, Macquarie Pk, NSW, Australia
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2019年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：39 / 39
页数：1
相关论文
共 50 条
  • [1] Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study
    Foley, Peter
    Spelman, Lynda
    Murrell, Dedee F.
    Mate, Eric
    Tronnberg, Rebecca
    Lowe, Patricia M.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 (03) : 312 - 320
  • [2] Effectiveness and safety of secukinumab in Chinese patients with plaque psoriasis in a clinical practice setting: a pilot study
    Zhu, Si-Man
    Wang, Wen-Hui
    Guo, Jin-Zhu
    Guan, Xin
    Men, Yue-Hua
    Zhang, Hua
    Zhao, Yi-Ming
    Zhang, Chun-Lei
    CHINESE MEDICAL JOURNAL, 2020, 133 (24) : 3017 - 3019
  • [3] Effectiveness and safety of secukinumab in Chinese patients with plaque psoriasis in a clinical practice setting: a pilot study
    Zhu Si-Man
    Wang Wen-Hui
    Guo Jin-Zhu
    Guan Xin
    Men Yue-Hua
    Zhang Hua
    Zhao Yi-Ming
    Zhang Chun-Lei
    中华医学杂志(英文版), 2020, 133 (24) : 3017 - 3019
  • [4] Etanercept Improves Quality of Life Outcomes and Treatment Satisfaction in Patients with Moderate to Severe Plaque Psoriasis in Clinical Practice
    Vender, Ron
    Lynde, Charles
    Gilbert, Martin
    Ho, Vincent
    Sapra, Sheetal
    Poulin-Costello, Melanie
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2012, 16 (06) : 407 - 416
  • [5] Tildrakizumab improves the quality of life of patients with moderate to severe chronic plaque psoriasis in daily practice
    Tsianakas, Athanasios
    Ostendorf, Rolf
    Diemert, Sebastian
    Asadullah, Khusru
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 75 - 75
  • [6] Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study)
    Foley, Peter
    Manuelpillai, Nick
    Dolianitis, Con
    Cains, Geoffrey D.
    Mate, Eric
    Tronnberg, Rebecca
    Baker, Christopher
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 (03) : 303 - 311
  • [7] Secukinumab Treatment of moderate to severe Plaque Psoriasis in the clinical Routine Care: Baseline Characteristics of Psoriasis Patients at the Beginning of the PROSPECT Study
    Korber, A.
    von Kiedrowski, R.
    Kraehn-Senftleben, G.
    Schwinn A
    Hagemeier, H. H.
    Bachhuber, T.
    Kasparek, T.
    Amon, U.
    Augustin, M.
    Thaci, D.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 137 - 138
  • [8] Clinical responses to treatment and changes in the Dermatology Life Quality Index (DLQI) in moderate to severe plaque psoriasis patients treated with adalimumab
    Shikiar, R
    Thompson, C
    Melilli, LE
    VALUE IN HEALTH, 2005, 8 (06) : A13 - A13
  • [9] Effectiveness and safety of secukinumab in patients with moderate-to-severe plaque psoriasis - a real life retrospective study
    Galica, Katarzyna
    Lesiak, Aleksandra
    Ciazynska, Magdalena
    Noweta, Marcin
    Bednarski, Igor
    Narbutt, Joanna
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2021, 38 (06): : 973 - 978
  • [10] Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain
    Notario, Jaime
    Deza, Gustavo
    Vilarrasa, Eva
    Valenti, Francesc
    Munoz, Carlos
    Mollet, Jordi
    Rocamora, Vicenc
    Carrascosa, Jose-Manuel
    del Alcazar, Elena
    Alsina, Merce
    Vidal, David
    Puig, Lluis
    Lopez-Ferrer, Anna
    Riera, Jose
    Gallardo, Fernando
    Ferran, Marta
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2019, 30 (05) : 424 - 429
12345